Recent News

• 06.12.2025 - Intensity Therapeutics, Inc. Announces Pricing of Public Offering
• 06.11.2025 - Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
• 06.11.2025 - Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
• 05.29.2025 - Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
• 05.28.2025 - Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon
• 05.13.2025 - Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.06.2025 - Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Recent Filings

• 06.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.11.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 06.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.06.2025 - 8-K Current report
• 06.02.2025 - ARS Annual Report to Security Holders
• 06.02.2025 - DEF 14A Other definitive proxy statements
• 06.02.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.20.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]